Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2011, Article ID 575840, 9 pages
http://dx.doi.org/10.1155/2011/575840
Review Article

Lipid Abnormalities and Cardiometabolic Risk in Patients with Overt and Subclinical Thyroid Disease

1Endocrine Unit, Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece
2Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece

Received 3 May 2011; Revised 17 May 2011; Accepted 17 May 2011

Academic Editor: Angeliki Chroni

Copyright © 2011 Melpomeni Peppa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. G. Hollowell, N. W. Staehling, W. D. Flanders et al., “Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III),” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 2, pp. 489–499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Kim, “Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate,” Thyroid, vol. 18, no. 2, pp. 141–144, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. X. Zhu and S. Y. Cheng, “New insights into regulation of lipid metabolism by thyroid hormone,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 5, pp. 408–413, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. B. Biondi and I. Klein, “Hypothyroidism as a risk factor for cardiovascular disease,” Endocrine, vol. 24, no. 1, pp. 1–13, 2004. View at Google Scholar · View at Scopus
  5. B. Biondi and G. J. Kahaly, “Cardiovascular involvement in patients with different causes of hyperthyroidism,” Nature Reviews Endocrinology, vol. 6, no. 8, pp. 431–443, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. I. Klein and K. Ojamaa, “Thyroid hormone and the cardiovascular system,” The New England Journal of Medicine, vol. 344, no. 7, pp. 501–509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi, “Effects of thyroid hormone on the cardiovascular system,” Recent Progress in Hormone Research, vol. 59, pp. 31–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. N. A. Cachefo, P. Boucher, C. Vidon, E. Dusserre, F. Diraison, and M. Beylot, “Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5353–5357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. Abrams, S. M. Grundy, and H. Ginsberg, “Metabolism of plasma triglycerides in hypothyroidism and hyperthyroidism in man,” Journal of Lipid Research, vol. 22, no. 2, pp. 307–322, 1981. View at Google Scholar
  10. K. S. L. Lam, M. K. Chan, and R. T. T. Yeung, “High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction—effects of treatment,” Quarterly Journal of Medicine, vol. 59, no. 229, pp. 513–521, 1986. View at Google Scholar
  11. R. M. Krauss, R. I. Levy, and D. S. Fredrickson, “Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia,” Journal of Clinical Investigation, vol. 54, no. 5, pp. 1107–1124, 1974. View at Google Scholar
  12. K. C. B. Tan, S. W. M. Shiu, and A. W. C. Kung, “Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 8, pp. 2921–2924, 1998. View at Publisher · View at Google Scholar
  13. M. Heimberg, J. O. Olubadewo, and H. G. Wilcox, “Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states,” Endocrine Reviews, vol. 6, no. 4, pp. 590–607, 1985. View at Google Scholar · View at Scopus
  14. Y. Y. Liu and G. A. Brent, “Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation,” Trends in Endocrinology and Metabolism, vol. 21, no. 3, pp. 166–173, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. A. Berti, M. E. C. Amaral, A. C. Boschero et al., “Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice,” Metabolism, vol. 50, no. 5, pp. 530–536, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. I. Tancevski, A. Wehinger, E. Demetz et al., “Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5′-triphosphate-binding cassette transporter 1 expression,” Endocrinology, vol. 149, no. 7, pp. 3708–3712, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. Sauter, M. Weiss, and R. Hoermann, “Cholesterol 7α-hydroxylase activity in hypothyroidism and hyperthyroidism in humans,” Hormone and Metabolic Research, vol. 29, no. 4, pp. 176–179, 1997. View at Google Scholar · View at Scopus
  18. V. A. B. Drover and L. B. Agellon, “Regulation of the human cholesterol 7α-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice,” Endocrinology, vol. 145, no. 2, pp. 574–581, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. A. Santi, M. M. M. F. Duarte, R. N. Moresco et al., “Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 11, pp. 1635–1639, 2010. View at Publisher · View at Google Scholar · View at PubMed
  20. N. Nanda, Z. Bobby, and A. Hamide, “Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 5, pp. 674–679, 2008. View at Publisher · View at Google Scholar · View at PubMed
  21. D. G. Yavuz, M. Yüksel, O. Deyneli, Y. Ozen, H. Aydin, and S. Akalin, “Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients,” Clinical Endocrinology, vol. 61, no. 4, pp. 515–521, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. V. Sundaram, A. N. Hanna, L. Koneru, H. A. I. Newman, and J. M. Falko, “Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 10, pp. 3421–3424, 1997. View at Publisher · View at Google Scholar
  23. F. Costantini, S. D. Pierdomenico, D. De Cesare et al., “Effect of thyroid function on LDL oxidation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 732–737, 1998. View at Google Scholar
  24. T. Diekman, P. N. M. Demacker, J. J. P. Kastelein, A. F. H. Stalenhoef, and W. M. Wiersinga, “Increased oxidizability of low-density lipoproteins in hypothyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 5, pp. 1752–1755, 1998. View at Publisher · View at Google Scholar
  25. M. Peppa, C. Koliaki, P. Nikolopoulos, and S. A. Raptis, “Skeletal muscle insulin resistance in endocrine disease,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 527850, 2010. View at Publisher · View at Google Scholar · View at PubMed
  26. E. Maratou, D. J. Hadjidakis, A. Kollias et al., “Studies of insulin resistance in patients with clinical and subclinical hypothyroidism,” European Journal of Endocrinology, vol. 160, no. 5, pp. 785–790, 2009. View at Publisher · View at Google Scholar · View at PubMed
  27. E. Maratou, D. J. Hadjidakis, M. Peppa et al., “Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism,” European Journal of Endocrinology, vol. 163, no. 4, pp. 625–630, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. T. Tagami, T. Tamanaha, S. Shimazu et al., “Lipid profiles in the untreated patients with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical hypothyroidism with Hashimoto thyroiditis,” Endocrine Journal, vol. 57, no. 3, pp. 253–258, 2010. View at Google Scholar
  29. T. Tzotzas, G. E. Krassas, T. Konstantinidis, and M. Bougoulia, “Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment,” Thyroid, vol. 10, no. 9, pp. 803–808, 2000. View at Google Scholar
  30. P. D. F. D. S. Teixeira, V. S. Reuters, M. M. Ferreira et al., “Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure,” Translational Research, vol. 151, no. 4, pp. 224–231, 2008. View at Publisher · View at Google Scholar · View at PubMed
  31. T. W. A. de Bruin, H. Van Barlingen, M. Van Linde-Sibenius Trip, A. R. R. Van Vuurst de Vries, M. J. Akveld, and D. W. Erkelens, “Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 1, pp. 121–126, 1993. View at Publisher · View at Google Scholar
  32. A. Raziel, B. Rosenzweig, V. Botvinic et al., “The influence of thyroid function on serum lipid profile,” Atherosclerosis, vol. 41, no. 2-3, pp. 321–326, 1982. View at Google Scholar
  33. J. J. Staub, B. U. Althaus, H. Engler et al., “Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues,” American Journal of Medicine, vol. 92, no. 6, pp. 631–642, 1992. View at Publisher · View at Google Scholar
  34. R. P. F. Dullaart, J. J. van Doormaal, K. Hoogenberg, and W. J. Sluiter, “Triiodothyronine rapidly lowers plasma lipoprotein (a) in hypothyroid subjects,” Netherlands Journal of Medicine, vol. 46, no. 4, pp. 179–184, 1995. View at Publisher · View at Google Scholar
  35. A. N. Torun, S. Kulaksizoglu, M. Kulaksizoglu, B. O. Pamuk, E. Isbilen, and N. B. Tutuncu, “Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism,” Clinical Endocrinology, vol. 70, no. 3, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. A. Becerra, D. Bellido, A. Luengo, G. Piédrola, and D. A. De Luis, “Lippprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy,” Clinical Nutrition, vol. 18, no. 5, pp. 319–322, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. I. C. Klausen, F. E. Nielsen, L. Hegedus, L. U. Gerdes, P. Charles, and O. Faergeman, “Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a),” Metabolism, vol. 41, no. 8, pp. 911–914, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Ito, T. Arishima, T. Kudo et al., “Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 608–611, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. Paoli, G. Bellabarba, E. Velazquez et al., “Sex steroids, lipids, and lipoprotein cholesterols in women with subclinical and overt hypothyroidism before and after L-thyroxine therapy,” Clinica Chimica Acta, vol. 275, no. 1, pp. 81–91, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Pazos, J. J. Alvarez, J. Rubies-Prat, C. Varela, and M. A. Lasuncion, “Long term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 2, pp. 562–566, 1995. View at Google Scholar · View at Scopus
  41. M. L. Martánez-Triguero, A. Hernández-Mijares, T. T. Nguyen et al., “Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism,” Mayo Clinic Proceedings, vol. 73, no. 9, pp. 837–841, 1998. View at Google Scholar · View at Scopus
  42. T. O'Brien, K. Katz, D. Hodge, T. T. Nguyen, B. A. Kottke, and I. D. Hay, “The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E,” Clinical Endocrinology, vol. 46, no. 1, pp. 17–20, 1997. View at Google Scholar · View at Scopus
  43. R. Arem, D. A. Escalante, N. Arem, J. D. Morrisett, and W. Patsch, “Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a),” Metabolism, vol. 44, no. 12, pp. 1559–1563, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Caraccio, E. Ferrannini, and F. Monzani, “Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 4, pp. 1533–1538, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Monzani, N. Caraccio, M. Kozàkowà et al., “Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2099–2106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. Z. Efstathiadou, S. Bitsis, H. J. Milionis et al., “Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial?” European Journal of Endocrinology, vol. 145, no. 6, pp. 705–710, 2001. View at Google Scholar · View at Scopus
  47. A. Iqbal, R. Jorde, and Y. Figenschau, “Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study,” Journal of Internal Medicine, vol. 260, no. 1, pp. 53–61, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. M. Adrees, J. Gibney, N. El-Saeity, and G. Boran, “Effects of 18 months of l-T4 replacement in women with subclinical hypothyroidism,” Clinical Endocrinology, vol. 71, no. 2, pp. 298–303, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. S. Miura, M. Iitaka, H. Yoshimura et al., “Disturbed lipid metabolism in patients with subclinical hypothyroidism: effect of L-thyroxine therapy,” Internal Medicine, vol. 33, no. 7, pp. 413–417, 1994. View at Google Scholar · View at Scopus
  50. A. W. C. Kung, R. W. C. Pang, and E. D. Janus, “Elevated serum lipoprotein(a) in subclinical hypothyroidism,” Clinical Endocrinology, vol. 43, no. 4, pp. 445–449, 1995. View at Google Scholar · View at Scopus
  51. M. Ito, J. Takamatsu, I. Sasaki et al., “Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism,” American Journal of Medicine, vol. 117, no. 9, pp. 696–699, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. E. S. Ganotakis, K. Mandalaki, M. Tampakaki et al., “Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy,” Angiology, vol. 54, no. 5, pp. 569–576, 2003. View at Google Scholar · View at Scopus
  53. S. K. Kim, S. H. Kim, K. S. Park, S. W. Park, and Y. W. Cho, “Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement,” Endocrine Journal, vol. 56, no. 6, pp. 753–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. W. J. Hueston and W. S. Pearson, “Subclinical hypothyroidism and the risk of hypercholesterolemia,” Annals of Family Medicine, vol. 2, no. 4, pp. 351–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. K. A. Shakoor, A. Aldibbiat, L. E. Ingoe et al., “Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 319–322, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. R. J. Bell, L. Rivera-Woll, S. L. Davison, D. J. Topliss, S. Donath, and S. R. Davis, “Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease—a community-based study,” Clinical Endocrinology, vol. 66, no. 4, pp. 548–556, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. J. Kvetny, P. E. Heldgaard, E. M. Bladbjerg, and J. Gram, “Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years,” Clinical Endocrinology, vol. 61, no. 2, pp. 232–238, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. Yildirimkaya, M. Özata, K. Yilmaz, C. Kilinç, M. A. Gündoğan, and T. Kutluay, “Lipoprotein(a) Concentration in Subclinical Hypothyroidism before and after Levo-Thyroxine Therapy,” Endocrine Journal, vol. 43, no. 6, pp. 731–736, 1996. View at Google Scholar
  59. P. Caron, C. Calazel, H. J. Parra, M. Hoff, and J. P. Louvet, “Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy,” Clinical Endocrinology, vol. 33, no. 4, pp. 519–523, 1990. View at Google Scholar
  60. Y. Lai, J. Wang, F. Jiang et al., “The relationship between serum thyrotropin and components of metabolic syndrome,” Endocrine Journal, vol. 58, no. 1, pp. 23–30, 2011. View at Publisher · View at Google Scholar
  61. H. J. Milionis, Z. Efstathiadou, A. D. Tselepis et al., “Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine,” Thyroid, vol. 13, no. 4, pp. 365–369, 2003. View at Google Scholar
  62. G. Rondeau, N. Rutamucero, V. Messier et al., “Reference range thyroid-stimulating hormone is associated with physical activity energy expenditure in overweight and obese postmenopausal women: a Montreal-Ottawa New Emerging Team Study,” Metabolism, vol. 59, no. 11, pp. 1597–1602, 2010. View at Publisher · View at Google Scholar · View at PubMed
  63. G. A. Sigal, G. Medeiros-Neto, J. C. Vinagre, J. Diament, and R. C. Maranhão, “Lipid metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich lipoproteins and lipid transfers to high-density lipoprotein before and after levothyroxine treatment,” Thyroid, vol. 21, no. 4, pp. 347–353, 2011. View at Publisher · View at Google Scholar · View at PubMed
  64. J. A. Franklyn, J. Daykin, J. Betteridge et al., “Thyroxine replacement therapy and circulating lipid concentrations,” Clinical Endocrinology, vol. 38, no. 5, pp. 453–459, 1993. View at Google Scholar
  65. M. Weintraub, I. Grosskopf, Y. Trostanesky, G. Charach, A. Rubinstein, and N. Stern, “Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2532–2536, 1999. View at Google Scholar
  66. C. Meier, J. J. Staub, C. B. Roth et al., “TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (basel thyroid study),” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4860–4866, 2001. View at Publisher · View at Google Scholar
  67. R. Arem and W. Patsch, “Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy,” Archives of Internal Medicine, vol. 150, no. 10, pp. 2097–2100, 1990. View at Publisher · View at Google Scholar
  68. H. Nishitani, K. Okamura, S. Noguchi, K. Inoue, Y. Morotomi, and M. Fujishima, “Serum lipid levels in thyroid dysfunction with special reference to transient elevation during treatment in hyperthyroid graves' disease,” Hormone and Metabolic Research, vol. 22, no. 9, pp. 490–493, 1990. View at Google Scholar
  69. X. Guang-Da, C. Hong-Yan, and Z. Xian-Mei, “Changes in endothelium-dependent arterial dilation before and after subtotal thyroidectomy in subjects with hyperthyroidism,” Clinical Endocrinology, vol. 61, no. 3, pp. 400–404, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. E. Muls, V. Blaton, and M. Rosseneu, “Serum lipids and apolipoproteins A-I, A-II, and B in hyperthyroidism before and after treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 55, no. 3, pp. 459–464, 1982. View at Google Scholar
  71. A. E. Altinova, F. B. Törüner, M. Aktürk et al., “Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism,” Clinical Endocrinology, vol. 65, no. 4, pp. 530–535, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. A. W. C. Kung, R. W. C. Pang, I. Lauder, K. S. L. Lam, and E. D. Janus, “Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism,” Clinical Chemistry, vol. 41, no. 2, pp. 226–231, 1995. View at Google Scholar
  73. I. C. Klausen, L. Hegedus, P. S. Hansen, F. E. Nielsen, L. U. Gerdes, and O. Faergeman, “Apolipoprotein(a) phonotypes and lipoprotein(a) concentrations in patients with hyperthyroidism,” Journal of Molecular Medicine, vol. 73, no. 1, pp. 41–46, 1995. View at Google Scholar
  74. M. Ozata, M. Yildirimkaya, K. Yilmaz et al., “The effects of thyroid status on serum apolipoprotein A-I-containing lipoprotein particles,” Hormone and Metabolic Research, vol. 30, no. 4, pp. 217–221, 1998. View at Google Scholar
  75. H. Hayashi, N. Mizushima, H. Yoshinaga et al., “The relationship between lipoprotein(a) and low density lipoprotein receptors during the treatment of hyperthyroidism,” Hormone and Metabolic Research, vol. 28, no. 8, pp. 384–387, 1996. View at Google Scholar
  76. F. Hoppichler, C. Sandholzer, R. Moncayo, G. Utermann, and H. G. Georg Kraft, “Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels,” Atherosclerosis, vol. 115, no. 1, pp. 65–71, 1995. View at Publisher · View at Google Scholar
  77. A. Berghout, J. van de Wetering, and P. Klootwijk, “Cardiac and metabolic effects in patients who present with a multinodular goitre,” Netherlands Journal of Medicine, vol. 61, no. 10, pp. 318–322, 2003. View at Google Scholar
  78. J. V. Parle, J. A. Franklyn, K. W. Cross, S. R. Jones, and M. C. Sheppard, “Circulating lipids and minor abnormalities of thyroid function,” Clinical Endocrinology, vol. 37, no. 5, pp. 411–414, 1992. View at Google Scholar
  79. B. Biondi, E. A. Palmieri, S. Fazio et al., “Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4701–4705, 2000. View at Publisher · View at Google Scholar
  80. V. Kotsis, M. Alevizaki, S. Stabouli et al., “Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study,” Journal of Hypertension, vol. 25, no. 5, pp. 993–999, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. I. Saito, K. Ito, and T. Saruta, “Hypothyroidism as a cause of hypertension,” Hypertension, vol. 5, no. 1, pp. 112–115, 1983. View at Google Scholar
  82. O. Mayer, J. Šimon, J. Filipovský, M. Pláškova, and R. Pikner, “Hypothyroidism in coronary heart disease and its relation to selected risk factors,” Vascular Health and Risk Management, vol. 2, no. 4, pp. 499–506, 2006. View at Publisher · View at Google Scholar
  83. M. Christ-Crain, C. Meier, M. Guglielmetti et al., “Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial,” Atherosclerosis, vol. 166, no. 2, pp. 379–386, 2003. View at Publisher · View at Google Scholar
  84. B. G. Nedrebø, U. B. Ericsson, O. Nygård et al., “Plasma total homocysteine levels in hyperthyroid and hypothyroid patients,” Metabolism, vol. 47, no. 1, pp. 89–93, 1998. View at Publisher · View at Google Scholar
  85. M. S. Morris, A. G. Bostom, P. F. Jacques, J. Selhub, and I. H. Rosenberg, “Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey,” Atherosclerosis, vol. 155, no. 1, pp. 195–200, 2001. View at Publisher · View at Google Scholar
  86. A. Squizzato, E. Romualdi, H. R. Büller, and V. E. A. Gerdes, “Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2415–2420, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. C. Erem, “Coagulation and fibrinolysis in thyroid dysfunction,” Endocrine, vol. 36, no. 1, pp. 110–118, 2009. View at Publisher · View at Google Scholar · View at PubMed
  88. R. Chadarevian, E. Bruckert, L. Leenhardt, P. Giral, A. Ankri, and G. Turpin, “Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 732–737, 2001. View at Publisher · View at Google Scholar
  89. M. Erdogan, A. Canataroglu, S. Ganidagli, and M. Kulaksızoglu, “Metabolic syndrome prevelance in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters,” Journal of Endocrinological Investigation. In press.
  90. G. Dimitriadis, P. Mitrou, V. Lambadiari et al., “Insulin action in adipose tissue and muscle in hypothyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4930–4937, 2006. View at Publisher · View at Google Scholar · View at PubMed
  91. O. Giménez-Palop, G. Giménez-Pérez, D. Mauricio et al., “Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes,” European Journal of Endocrinology, vol. 153, no. 1, pp. 73–79, 2005. View at Publisher · View at Google Scholar · View at PubMed
  92. A. Caixàs, R. Tirado, J. Vendrell et al., “Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters,” Clinical Endocrinology, vol. 71, no. 5, pp. 733–738, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. G. Dimitriadis, E. Maratou, E. Boutati et al., “IGF-I increases the recruitment of GLUT4 and GLUT3 glucose transporters on cell surface in hyperthyroidism,” European Journal of Endocrinology, vol. 158, no. 3, pp. 361–366, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. G. Dimitriadis, M. Parry-Billings, S. Bevan et al., “The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats,” European Journal of Clinical Investigation, vol. 27, no. 6, pp. 475–483, 1997. View at Google Scholar
  95. E. Çakal, A. T. Turgut, B. Demirbas et al., “Effects of L-thyroxine replacement therapy on carotid intima-media thickness in patients with primary hypothyroidism,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 6, pp. 294–300, 2009. View at Publisher · View at Google Scholar · View at PubMed
  96. T. Nagasaki, M. Inaba, Y. Kumeda et al., “Decrease of arterial stiffness at common carotid artery in hypothyroid patients by normalization of thyroid function,” Biomedicine and Pharmacotherapy, vol. 59, no. 1-2, pp. 8–14, 2005. View at Publisher · View at Google Scholar · View at PubMed
  97. L. Vanhaelst, P. Neve, and P. A. Bastenie, “Coronary-artery disease in myxoedema,” The Lancet, vol. 2, no. 7528, pp. 1257–1258, 1967. View at Google Scholar
  98. A. D. Steinberg, “Myxedema and coronary artery disease–a comparative autopsy study,” Annals of Internal Medicine, vol. 68, no. 2, pp. 338–344, 1968. View at Google Scholar
  99. A. I. Qureshi, M. F. K. Suri, A. Nasar, J. F. Kirmani, A. A. Divani, and W. H. Giles, “Free Thyroxine Index and risk of stroke: results from the National Health and Nutrition Examination Survey follow-up study,” Medical Science Monitor, vol. 12, no. 12, pp. CR501–CR506, 2006. View at Google Scholar
  100. D. Liu, F. Jiang, Z. Shan et al., “A cross-sectional survey of relationship between serum TSH level and blood pressure,” Journal of Human Hypertension, vol. 24, no. 2, pp. 134–138, 2010. View at Publisher · View at Google Scholar · View at PubMed
  101. T. Nagasaki, M. Inaba, Y. Kumeda et al., “Increased pulse wave velocity in subclinical hypothyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 154–158, 2006. View at Publisher · View at Google Scholar · View at PubMed
  102. Y. Duan, W. Peng, X. Wang et al., “Community-based study of the association of subclinical thyroid dysfunction with blood pressure,” Endocrine, vol. 35, no. 2, pp. 136–142, 2009. View at Publisher · View at Google Scholar · View at PubMed
  103. J. P. Walsh, A. P. Bremner, M. K. Bulsara et al., “Subclinical thyroid dysfunction and blood pressure: a community-based study,” Clinical Endocrinology, vol. 65, no. 4, pp. 486–491, 2006. View at Publisher · View at Google Scholar · View at PubMed
  104. F. Toruner, A. E. Altinova, A. Karakoc et al., “Risk factors for cardiovascular disease in patients with subclinical hypothyroidism,” Advances in Therapy, vol. 25, no. 5, pp. 430–437, 2008. View at Publisher · View at Google Scholar · View at PubMed
  105. E. Şengul, B. Çetinarslan, I. Tarkun, Z. Cantürk, and E. Türemen, “Homocysteine concentrations in subclinical hypothyroidism,” Endocrine Research, vol. 30, no. 3, pp. 351–359, 2004. View at Publisher · View at Google Scholar
  106. R. D. Lindeman, L. J. Romero, D. S. Schade, S. Wayne, R. N. Baumgartner, and P. J. Garry, “Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey,” Thyroid, vol. 13, no. 6, pp. 595–600, 2003. View at Google Scholar
  107. W. J. Hueston, D. E. King, and M. E. Geesey, “Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism,” Clinical Endocrinology, vol. 63, no. 5, pp. 582–587, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. R. Luboshitzky, A. Aviv, P. Herer, and L. Lavie, “Risk factors for cardiovascular disease in women with subclinical hypothyroidism,” Thyroid, vol. 12, no. 5, pp. 421–425, 2002. View at Google Scholar
  109. A. R. Cappola, L. P. Fried, A. M. Arnold et al., “Thyroid status, cardiovascular risk, and mortality in older adults,” Journal of the American Medical Association, vol. 295, no. 9, pp. 1033–1041, 2006. View at Publisher · View at Google Scholar · View at PubMed
  110. C. H. Jung, K. C. Sung, H. S. Shin et al., “Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio in Korea,” The Korean Journal of Internal Medicine, vol. 18, no. 3, pp. 146–153, 2003. View at Google Scholar
  111. A. Tuzcu, M. Bahceci, D. Gokalp, Y. Tuzun, and K. Gunes, “Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia,” Endocrine Journal, vol. 52, no. 1, pp. 89–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Razvi, J. U. Weaver, M. P. Vanderpump, and S. H. S. Pearce, “The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham survey cohort,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1734–1740, 2010. View at Publisher · View at Google Scholar · View at PubMed
  113. S. Singh, J. Duggal, J. Molnar, F. Maldonado, C. P. Barsano, and R. Arora, “Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis,” International Journal of Cardiology, vol. 125, no. 1, pp. 41–48, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. N. Rodondi, D. Aujesky, E. Vittinghoff, J. Cornuz, and D. C. Bauer, “Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis,” American Journal of Medicine, vol. 119, no. 7, pp. 541–551, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. N. Ochs, R. Auer, D. C. Bauer et al., “Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality,” Annals of Internal Medicine, vol. 148, no. 11, pp. 832–845, 2008. View at Google Scholar · View at Scopus
  116. S. Razvi, A. Shakoor, M. Vanderpump, J. U. Weaver, and S. H.S. Pearce, “The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 2998–3007, 2008. View at Publisher · View at Google Scholar · View at PubMed
  117. B. K. Goksel, M. Karatas, A. Nebioglu et al., “Subclinical hypothyroidism, hyperhomocysteinemia and dyslipidemia: investigating links with ischemic stroke in Turkish patients,” Neurological Research, vol. 29, no. 8, pp. 871–876, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. S. K. Jeong, J. Y. Seo, H. S. Nam, and H. K. Park, “Thyroid function and internal carotid artery stenosis in ischemic stroke,” Endocrine Journal, vol. 57, no. 8, pp. 711–718, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Alevizaki, M. Synetou, K. Xynos, C. C. Alevizaki, and K. N. Vemmos, “Hypothyroidism as a protective factor in acute stroke patients,” Clinical Endocrinology, vol. 65, no. 3, pp. 369–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. J. H. Baek, P. W. Chung, Y. B. Kim et al., “Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients,” Endocrine Journal, vol. 57, no. 1, pp. 23–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. N. Rodondi, A. B. Newman, E. Vittinghoff et al., “Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death,” Archives of Internal Medicine, vol. 165, no. 21, pp. 2460–2466, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. L. M. Prisant, J. S. Gujral, and A. L. Mulloy, “Hyperthyroidism: a secondary cause of isolated systolic hypertension,” Journal of Clinical Hypertension, vol. 8, no. 8, pp. 596–599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. K. M. Colleran, D. M. Ratliff, and M. R. Burge, “Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events,” Endocrine Practice, vol. 9, no. 4, pp. 290–295, 2003. View at Google Scholar
  124. P. Mitrou, E. Boutati, V. Lambadiari et al., “Insulin resistance in hyperthyroidism: the role of IL6 and TNFα,” European Journal of Endocrinology, vol. 162, no. 1, pp. 121–126, 2010. View at Publisher · View at Google Scholar · View at PubMed
  125. G. Dimitriadis, P. Mitrou, V. Lambadiari et al., “Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 1112–1118, 2006. View at Publisher · View at Google Scholar · View at PubMed
  126. J. Al Jaber, S. Haque, H. Noor, B. Ibrahim, and J. Al Suwaidi, “Thyrotoxicosis and coronary artery spasm: case report and review of the literature,” Angiology, vol. 61, no. 8, pp. 807–812, 2010. View at Google Scholar · View at Scopus
  127. R. A. Chudleigh and J. S. Davies, “Graves' thyrotoxicosis and coronary artery spasm,” Postgraduate Medical Journal, vol. 83, no. 985, article e5, 2007. View at Google Scholar
  128. Y. H. Choi, J. H. Chung, S. W. Bae et al., “Severe coronary artery spasm can be associated with hyperthyroidism,” Coronary Artery Disease, vol. 16, no. 3, pp. 135–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. J. J. Sheu, J. H. Kang, H. C. Lin, and H. C. Lin, “Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study,” Stroke, vol. 41, no. 5, pp. 961–966, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. J. S. Staffurth, M. C. Gibberd, and S. N. Fui, “Arterial embolism in thyrotoxicosis with atrial fibrillation,” British Medical Journal, vol. 2, no. 6088, pp. 688–690, 1977. View at Google Scholar · View at Scopus
  131. S. Bar-Sela, M. Ehrenfeld, and M. Eliakim, “Arterial embolism in thyrotoxicosis with atrial fibrillation,” Archives of Internal Medicine, vol. 141, no. 9, pp. 1191–1192, 1981. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Squizzato, V. E. A. Gerdes, D. P. M. Brandjes, H. R. Büller, and J. Stam, “Thyroid diseases and cerebrovascular disease,” Stroke, vol. 36, no. 10, pp. 2302–2310, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. H. Völzke, T. Ittermann, C. O. Schmidt et al., “Subclinical hyperthyroidism and blood pressure in a population-based prospective cohort study,” European Journal of Endocrinology, vol. 161, no. 4, pp. 615–621, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. H. Völzke, D. M. Robinson, U. Schminke et al., “Thyroid function and carotid wall thickness,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2145–2149, 2004. View at Publisher · View at Google Scholar